Our COVID19 phase 2 clinical trial for our lead product, rhu-pGSN, has begun.

Share on facebook
Share on twitter
Share on linkedin

August 20, 2020: WIB-Metro New York – Biotech Leadership in the time of COVID-19: Impact, Opportunity, and Resilience

The leadership team of BioAegis Therapeutics will share their experiences this year as they reframed their strategy to address the COVID-19 threat to their employees and hustled to initiate a COVID-19 clinical trial for severe COVID-19 patients.

When:Thursday, August 20, 2020
12:00 p.m. – 1:00 p.m. EDT
Where:Online (GoToWebinar)
Contact:WIB-Metro New York